Sungmin Woo, MD, and colleagues
at the Seoul National University studied
318 patients who underwent MRI followed
by RP. After a median follow-up
of 104 months, 11 patients (3.5%) died
from prostate cancer.

Of the 318 patients, 104
(32.7%) had clinically significant cancer
on MRI. These patients had 5- and
10-year PCSM rates of 8% and 14.2%,
respectively, whereas patients without
clinical significant cancer had rates of
0% and 0.5%, respectively, the investigators
reported online in Acta Radiologica.
In multivariate analysis, clinically significant cancer on MRI was associated with
an 11-fold increased risk of PCSM.